The most difficult, and perhaps, most important decision that a clinician makes for a patient on the liver transplant wait-list is when 'not' to proceed with liver transplant. Although an individual may be suitable for transplant surgery at listing, he/she may become too sick while waiting.
INTRODUCTION
Half a century after Dr Thomas Starzl performed the first human liver transplant, liver transplantation has become a well accepted treatment option for patients with end-stage liver disease. The decision to list a patient for liver transplant is now standardized and straightforward. In general, a patient with an indication for transplant (e.g., decompensated cirrhosis, hepatocellular carcinoma), adequate social support, well-controlled medical comorbidities, and absence of active substance use is eligible for listing. But the condition of a transplant candidate is dynamic; although an individual may be suitable for transplant surgery at listing, she/he may become too sick while waiting. There is little consensus, however, on when 'not' to proceed with transplantation, and as a result, this threshold for 'too sick' varies by patient, provider, and program. This article discusses specific conditions that often emerge in candidates after listing and may raise concerns by transplant teams regarding transplant suitability. I will then provide a framework for making this high-stakes decision to proceed, or not, with liver transplant surgery.
Advancing age, sarcopenia, acute on chronic liver failure, and nonliver-related medical comorbidities are common conditions that arise while on the wait-list that can render a patient too sick for transplant.
Objective assessments of physical frailty enable us to evaluate the extent to which pretransplant conditions will impair both quality of life and survival after liver transplant.
A framework that incorporates pretransplant assessments of physical frailty to identify those patients who are highly vulnerable to adverse outcomes after transplant can facilitate the decision regarding whether a patient is too sick for transplant. Diabetes: HR 1.4 (95% CI 1.0-1.9) [9] COPD: HR 1.7 (95% CI 1.1-6.5) [9] Chronic renal insufficiency: HR 1.6 (95% CI 1.2-2.3) [9] between age and laboratory MELD at transplant [14] . Furthermore, the development of pretransplant diabetes or need for mechanical ventilation prior to transplant are associated with poor outcomes after transplant among older recipients [11] , and should be considered factors that make an 'older' adult too sick for liver transplant. Clearly, ongoing assessment of transplant suitability as older candidate's age further on the wait-list is warranted.
Sarcopenia
Sarcopenia is a term that refers to severe loss of muscle mass [15 & ]. Most commonly quantified by abdominal skeletal muscle area on cross-sectional imaging, sarcopenia has been reported in 38-66% of patients with cirrhosis [16,17 & ,18 ]. Pretransplant sarcopenia is strongly associated with transplant-related outcomes. In a study of 142 liver transplant candidates, sarcopenia was associated with an over two-fold increased hazard of mortality, adjusted for MELD and age (Table 1 ) [3] . After liver transplant, every 1000 mm 2 increase in skeletal muscle area of the psoas at the 4th lumbar vertebra was associated with a 73% decreased risk of mortality (n ¼ 163 liver transplant recipients; Table 1 ) [4] . Posttransplant survival among liver transplant recipients with the highest compared with lowest quartiles of total psoas muscle area were 87% and 50% at 1-year and 77% and 26% at 3-years [4] . Using low body mass index as an approximation of sarcopenia, liver transplant recipients with a BMI less than 18.5 kg/m 2 (n ¼ 863) experienced a higher risk of death (HR 1.4; 95% CI 1.2-1.7) and graft loss (HR 1.3; 95% CI 1.1-1.5) compared with recipients with a BMI of 18.5-24.9 kg/m 2 [19] . Given significantly inferior outcomes among liver transplant candidates and recipients with low muscle mass, sarcopenia should be considered a criterion for being too sick for transplant.
Acute on chronic liver failure
Acute on chronic liver failure (ACLF) is defined as a syndrome in patients with chronic liver disease with or without previously diagnosed cirrhosis which is characterized by acute hepatic decompensation resulting in liver failure and one or more extrahepatic organ failures that is associated with increased mortality within a period of 28 days and up to 3 months from onset [20] . In the absence of transplant, mortality at 28 and 90 days increases with grade of ACLF: 22% and 41% for ACLF Grade 1, 32% and 52% for ACLF Grade 2, and 77% and 79% for ACLF Grade 3 [5] .
Early transplant, defined as within 28 days of ACLF onset, is associated with significantly improved survival compared with those who did not receive transplant, with a probability of 1-year survival after transplant of 75% compared with 10% survival without transplant (P < 0.001) [6 & ]. However, the presence of multiorgan failure and associated infections that constitute this clinical syndrome often render a patient too sick for transplant.
Medical comorbidities
Preexisting medical conditions that are unrelated to the underlying liver disease will not improve, and may even worsen, after liver transplant. Such conditions include coronary artery disease, diabetes, peripheral arterial disease, hyperlipidemia, and chronic obstructive pulmonary disease (COPD). Because of selection of recipients with only well controlled conditions, our ability to assess the impact of specific preexisting nonliver-related conditions on posttransplant outcomes is limited and the data are conflicting. In a study of US liver transplant recipients from 2002 to 2006, obesity, defined as a BMI > 35 kg/m 2 , was the only preexisting condition that was associated with posttransplant mortality (Table 1) [7] . Diabetes, COPD, peripheral arterial disease, angina, or coronary artery disease were not. In a separate study utilizing the UK national liver transplant registry, only cardiovascular disease was identified as a risk factor for long-term mortality after liver transplant (Table  1 ) [8] . Similarly to the US cohort, diabetes, COPD, chronic renal insufficiency, or connective tissue disease did not emerge as predictors of mortality [8] . However, in a single-center study (n ¼ 624) that evaluated more granular-level data on medical comorbidities, coronary artery disease, diabetes, COPD, and chronic renal insufficiency were each associated with an increased adjusted risk of mortality after liver transplant (Table 1) [9] . Given the conflicting results between data from large administrative databases vs. the smaller but more granular single-center cohort, better methods to assess the impact of preexisting medical comorbidities on transplant-related outcomes are needed.
PRETRANSPLANT ASSESSMENT OF TRANSPLANT SUITABILITY
While we might all agree that these conditions raise concerns about a candidate's suitability for transplant surgery, each condition, in isolation, is often not sufficient to overcome the enormous pressure to proceed with transplantation from the patient, caregivers, and transplant team that accumulates with time on the wait-list. How does one 'sum' the above conditions to determine whether a patient has reached the threshold of being too sick for transplant?
One answer lies in the assessment of physical frailty. Originally developed in the field of geriatrics, 'frailty' is a biological syndrome of increased vulnerability to stressors that predisposes patients to adverse health outcomes including frequent hospitalizations, institutionalization, and ultimately, death [21,22 && ]. Although many tools have been developed in geriatric cohorts to capture various aspects of physical frailty, all measures have the common goal of 'objectively' identifying the external manifestation of this vulnerability. Several of these tools, the Fried Frailty Index, Short Physical Performance Battery, 6-minute walk test, and Activities of Daily Living scale, have been studied in patients with endstage liver disease and demonstrate construct validity and prognostic value ( Table 2) .
How do assessments of physical frailty allow us to identify who is too sick for transplant beyond liver disease severity alone? Complications of cirrhosis and portal hypertension undoubtedly contribute to physical frailty. Indeed, higher MELD scores and higher rates of ascites and hepatic encephalopathy are observed in frail compared with nonfrail liver transplant candidates [22 && ,23 && ]. But, as clinicians, we have all seen end-stage liver disease physically impact patients in very different ways that are not reflected by their MELD score or simply by the presence of ascites. Conceptually, tools to objectively measure physical frailty allow us to quantify 'the extent to which' complications of cirrhosis negatively impact outcomes. For example, a physically robust candidate who decompensates after a variceal bleed will be able to be quickly extubated after endoscopy, recover from acute on chronic liver failure, and be eligible for transplant. A frail candidate with the same complication may find himself with ventilator dependence from aspiration pneumonia, ileus (from prolonged immobility), then with refractory encephalopathy (from inability to administer lactulose), and be unsuitable.
Perhaps more importantly, objective assessments of physical frailty allow us to measure the extent to which extrahepatic comorbidities, such as advancing age and diabetes, will impact outcomes. This is critical, as medical comorbidities 'unrelated' to the underlying liver disease will persist, if not worsen, after liver transplant. For example, advancing age, in and of itself, may not present as physical frailty -we have all seen a number of 'youthful' 75 year olds. But a 75-year-old individual with diabetes requiring insulin and coronary artery disease requiring intervention is likely to manifest at least some degree of physical inactivity, weakness, slowed gait, or difficulty with chair stands (i.e., components of the frailty measures) that represent his increased vulnerability to adverse posttransplant outcomes. Add advanced sarcopenia, and he/she is at high risk for a complicated postoperative course that will severely reduce his quality of life, if not survival, after transplant.
FRAMEWORK FOR DETERMINING THE THRESHOLD FOR 'TOO SICK FOR TRANSPLANT'
While there are no absolute criteria for the threshold for 'too sick for transplant', I propose a framework, incorporating pretransplant assessments of physical frailty, to identify patients who will not achieve optimal outcomes after liver transplant (Fig. 1) . In this framework, pretransplant assessments of physical frailty represent the components that are unlikely to reverse after liver function returns (e.g., autonomic dysfunction from long-standing diabetes), or will take so long to reverse (e.g., sarcopenia) that the patient will be highly vulnerable to postoperative complications such as poor wound healing, hospital-acquired, or opportunistic infections. Candidate A, who is physically robust and, therefore, has sufficient physiological reserve to withstand surgery, will achieve rapid return to full function and enjoy long survival and high quality of life. Candidate B, who is physically 'prefrail', may experience several hospital readmissions and require institutionalization after discharge for rehabilitation. However, with careful optimization of certain transplant factors (e.g., transplant at a low MELD score, use of a high quality donor), Candidate B can ultimately achieve a favorable outcome.
Candidate C, who is physically frail, has so little physiologic reserve that even in the most optimal of transplant circumstances is at high risk for a complicated postoperative course that will impair his ability to achieve a high quality of life after transplant and reduce his survival. It is this patient, Candidate C, who is too sick for transplant.
CONCLUSION
The most challenging, and perhaps, the most important decision that a transplant clinician makes is when 'not' to proceed with liver transplant. While it is a highly individualized decision, pretransplant assessments of physical frailty can help us identify the combination of factors that will not reverse after transplant and therefore increase a patient's vulnerability to adverse posttransplant outcomes. We can then incorporate these assessments into the conceptual framework proposed in this study. This framework can be used not only to facilitate our decision about whether or not to proceed with transplant, but also to facilitate the discussion with our patients about what liver transplant can reasonably achieve. [26] .) Transplant responsive (e.g., liver dysfunction, ascites, encephalopathy). Transplant nonresponsive (e.g., older age, multimorbidity, advanced undernutrition/sarcopenia) Measured by physical frailty.
